dehydrogenase (LDH) level . Direct antiglobulin test was negative. A computerized tomography (CT) scan was performed showing acute right and left portal vein thrombosis . PNH was suspected confirmed with flow cytometry. Anticoagulation therapy using low molecular weight heparin was started associated with folic acid and blood transfusion. Treatment with monoclonal antibody Eculizumab could not be used because of its non availability. A slight improvement was initially noted with relief of his abdominal pain and decrease of LDH but few days later he presented a sub-occlusive syndrome with dyspnea and acute hemolysis. He was admitted than in the intensive care unit where he dead because of massive pulmonary embolism Conclusions: HPN is a rare acquired hematologic disorder with various clinical manifestations. Thrombosis can be the first manifestation of this disease. Prognosis has significantly improved owing to Eculizumab. P1.11.145. ASSOCIATION OF GENES POLYMORPHISMS WITH WARFARIN DOSE REQUIREMENT IN GEORGIAN POPULATION G. Tchitashvili 1 , N. Kakauridze 2 , T. Buadze 3 , M. Gaiozishvili 2 , T. Lezhava 3 . 1 Division of Genetics, Department of Biology,Ivane Javakhishvili Tbilisi State University, Tbilisi, Georgia; 2 Department of Internal Medicine, Faculty of Medicine, Tbilisi State Medical University, Georgia; 3 Ivane Javakhishvili Tbilisi State University, Georgia Aim: The aim of our research was to study the frequency of different alleles of VKROC1 and CYP2C9 genes for healthy donors and patients with thrombosis, in Georgian population. Methods: Genotyping of peripheral blood samples for studied genes al- leles was carried out using a tube scanner (ESE Quant Tube Scanner - is a small easy-to-use fluorescence measurement system), which gives possi- bility to identify SNPs. Results: In the studied group of patients with thrombosis the wild-type homozygous genotype - by the VKORC1 gene was e 60 %; heterozygous e 34 %; mutant homozygous e 6 %. In the healthy donor’s group this pattern was a little different: predominated heterozygous genotype (45 %); ho- mozygous wild type was - 40%; mutant homozygous -15 %. By CYP2C9 gene, in patients with thrombosis, the homozygous wild and heterozygous genotypes were 41% and 44%, respectively; mutant homo- zygous were revealed the ratio 11%. On the other hand, in healthy donors, the frequency of wild-type homozygous was 67%, heterozygous and mutant homozygous were 32 % and 1 % - respectively Conclusions: VKORC1 and /or CYP2C9 genes polymorphisms are pre- sented in numerous clinical dosing algorithms and clinical trials. It is revealed the significant variation of genotypes in patients with throm- bosis, which indicates the importance of genotype testing in treatment process, as well as for the prevention of thrombosis. P1.11.146. ONE-YEAR CARDIOVASCULAR OUTCOMES IN RUSSIAN ACS PATIENTS RECEIVING TICAGRELOR (STREAM STUDY) O. Apanova 2 , N. Gurina 2 , E. Oshchepkova 1 , B. Kvasnikov 2 . 1 National Medical Research Cardiology Centre of Russian Federation Ministry of Health, Moscow, Russia; 2 AstraZeneca Russia, Moscow, Russia Aim: There are limited real-world data regarding long-term cardiovascular (CV) outcomes in patients with acute coronary syndrome (ACS), especially in those receiving the more potent P2Y12 inhibitor ticagrelor. The aim of this analysis is to describe 1-year CV outcomes in ACS patients enrolled in the prospective part of the STREAM study. Methods: The prospective part of the STREAM study (NCT02288260) is a single-arm, longitudinal cohort study that includes ACS patients who were discharged from hospital with ticagrelor 90 mg BID + aspirin. A descriptive analysis approach has been used to analyze study objectives. Follow-up of patients was performed every 3 months via phone calls. Enrolled patients (n¼1012) had been hospitalized for ACS within 24 hours of symptom onset; 92.9% underwent percutaneous coronary intervention (PCI). These patients had a diagnosis of ST-segment elevation myocardial infarction (MI) (n¼652), non-ST-segment elevation MI (n¼176), or unstable angina (n¼184). Results: Among 1012 enrolled patients, 94.9% (n¼960) had CV outcomes data. At 1 year, the cumulative incidence of CV death was 0.62% (n¼6); recurrent MI was observed in 0.83% (n¼8) of patients and stroke in 0.21% (n¼2). Urgent recurrent revascularization was performed in 0.94% (n¼9) of patients, and 6.35% (n¼61) had recurrent hospitalization due to CV disease. Conclusions: The rate of CV complications (CV death, MI, stroke, recurrent revascularization) observed in ACS patients taking ticagrelor 90 mg BID with aspirin in real-world practice during the first year of follow-up was low. P1.11.147. PHOTOMECHANICAL EFFECT OF Q-SWITCHED ND:YAG LASER ENHANCE THROMBOLYSIS USING OF PLGA- BASED ENCAPSULATED TISSUE PLASMINOGEN ACTIVATOR (TPA) NANOPARTICLES H. Mehrad 1 , J. Mahmoudi 2 , A. Keshavarz 3 , A. Rahimkhani 3 . 1 Islamic Azad University, Tabriz Branch- Faculty of Basic Sciences- Department of Physics, Tabriz, Iran; 2 Tabriz University of Medical Sciences, Neurosciences Research Center- Department of Neurosciences, Tabriz, Iran; 3 Islamic Azad University, Tabriz Branch- Faculty of Mechanic- Department of Bioengeenering, Tabriz, Iran Aim: Thrombus formation on a disrupted atherosclerotic plaque is a key event that leads to atherothrombosis. Atherothrombosis mediated acute clinical events such as myocardial infarction and stroke. The purpose of this study is to prepare encapsulated tissue plasminogen activator (tPA) and evaluate its effectiveness on thrombolysis using laser therapy in the rabbit model of atherothrombotic. Methods: Briefly, New Zealand white rabbits were submitted to femoral artery atherothrombotic occlusion by primary balloon injury followed 1.5% cholesterol- rich diet injury for 12 weeks and finally perivascular severe cold injury. Then treatment group underwent extracorporeal Q-switched ND:YAG laser ( WL¼ 532 nm, P¼ 30 w, PD¼ 5 ns) therapy accompanied by Poly(lactic-co-glycolic acid) (PLGA)- based encapsulated tPA nanoparticles administration. Results: Results from color- Doppler ultrasonography, B-mode ultraso- nography and histopathology, showed a significant reduction in the mean value for blood mean velocity and the percentage of luminal cross- sectional area of stenosis and a significant increase in the mean value for blood volume flow at the stenotic region in the treatment group compared with the other groups (p<0.05). Conclusions: Focal thrombus disruption mechanism was partly clarified as originated from micro-jet formation upon bubble collapse. The throm- bolysis process can be enhanced by delivering encapsulated- tPA into thrombosis during extracorporeal laser therapy based on the photome- chanical effect due to optical cavitation bubbles. High peak pressures of tens of Mpa could be tightly focused onto spot diameter of <0.0 1 mm due to transient cavitation and shock wave generation.Therefore, our studies could offer an alternative for currently existing method for athero- thrombosis. P1.11.148. CLOT FORMATION AND FIBRINOLYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROME AND HEALTHY VOLUNTEERS P. Savvinova 1 , A. Kalinskaya 1, 2 , A. Shpektor 1, 2 , E. Vasilieva 2 . 1 Moscow State University of Medicine and Dentistry, Cardiology Department, Moscow, Russia; 2 Moscow State University of Medicine and Dentistry, Laboratory of Atherothrombosis, Moscow, Russia Aim: Thrombosis plays a key role in the pathogenesis of ACS. The majority of studies shows different components of the process, but do not describe the process in general. The objective of our work was to analyze the dif- ference of clot formation and clot lysis between ACS patients and healthy volunteers. Abstracts / Atherosclerosis 275 (2018) e104ee255 e147